Enliven Therapeutics (ELVN) Treasury Shares (2019 - 2026)
Enliven Therapeutics (ELVN) reported Treasury Shares of $323008.0 for Q1 2026, up 233.72% on a YoY basis from $96789.0 in Q1 2025, and up 319.64% sequentially from $76973.0 in Q4 2025.
Enliven Therapeutics (ELVN) Treasury Shares (2019 - 2026) Analysis & Trends
Enliven Therapeutics (ELVN) has 7 years of Treasury Shares data on file, last reported at $323008.0 in Q1 2026.
- For the quarter ending Q1 2026, Treasury Shares rose 233.72% year-over-year to $323008.0; the trailing twelve-month figure through Mar 2026 stood at $323008.0 (up 233.72% YoY), and the FY2025 full-year result was $76973.0, up 1.09% from the prior year.
- Treasury Shares improved to $323008.0 in Q1 2026, from $76973.0 in the prior quarter.
- In the past five years, Treasury Shares ranged from a high of $425289.0 in Q1 2022 to a low of $17250.0 in Q3 2023.
- A 5-year average of $129134.2 and a median of $91251.0 in 2024 frame the typical range for Treasury Shares.
- Across the five-year window, Treasury Shares sank 91.92% in 2023 and jumped 435.17% in 2024, its largest moves.
- Tracing ELVN's Treasury Shares over 5 years: stood at $213443.0 in 2022, then plunged by 63.22% to $78505.0 in 2023, then dropped by 3.01% to $76145.0 in 2024, then climbed by 1.09% to $76973.0 in 2025, then soared by 319.64% to $323008.0 in 2026.
- Business Quant data shows ELVN's Treasury Shares at $323008.0 in Q1 2026, $76973.0 in Q4 2025, and $83577.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -21,709.08 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 265,401.92 |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 19.41 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 5.14 Mn |
| 10 | Enliven Therapeutics | 3.22 Bn | 3.22 Bn | - | 323,008.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 323,008.00 |
| Mar 31, 2026 | 323,008.00 |
| Dec 31, 2025 | 76,973.00 |
| Dec 31, 2025 | 76,973.00 |
| Sep 30, 2025 | 83,577.00 |
| Sep 30, 2025 | 83,577.00 |
| Jun 30, 2025 | 90,185.00 |
| Jun 30, 2025 | 90,185.00 |
| Mar 31, 2025 | 96,789.00 |
| Mar 31, 2025 | 96,789.00 |
| Dec 31, 2024 | 76,145.00 |
| Dec 31, 2024 | 76,145.00 |
| Sep 30, 2024 | 92,317.00 |
| Sep 30, 2024 | 92,317.00 |
| Jun 30, 2024 | 94,068.00 |
| Jun 30, 2024 | 94,068.00 |
| Mar 31, 2024 | 95,817.00 |
| Mar 31, 2024 | 95,817.00 |
| Dec 31, 2023 | 78,505.00 |
| Dec 31, 2023 | 78,505.00 |